ABL Diagnostics and CDL Pharma sign a €2.7 million contract until 2031

ABL Diagnostics, located in Woippy, has announced a multi-year contract extending to 2031 with a European pharmaceutical company. This partnership focuses on neurodegenerative diseases, involves 30 centers in 11 countries, and includes services provided by CDL Pharma, distributed by ABL Diagnostics. An advance payment of over €100,000 is planned, with the total amount potentially reaching €2.7 million. Revenue will be based on the performance of services related to clinical trial management.

The contract increases the visibility of ABL Diagnostics' future revenue, strengthening its value-added services activities in clinical research. According to Sales and Operations Manager Mohamed Errafyqy, this contract demonstrates their ability to manage complex clinical programs. However, growth forecasts for the neurodegenerative disease market remain uncertain.